SOGC point out that OC use in young BRCA1 carriers should be individualized, taking into account the risks and benefits [67], while ACOG state that given the magnitude of the potential benefits (e.g., ovarian and endometrial cancer risk reduction, pregnancy prevention, cycle regulation), OC use in carriers is appropriate if indicated, and use for cancer risk reduction is reasonable [26]. Here, BRCA1 is linked to cancer.